Navigation Links
Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patients
Date:8/23/2011

Amid the controversy surrounding the Food and Drug Administration's ruling that Avastin should no longer be used to treat metastatic breast cancer, a new multinational Phase III clinical trial shows that Avastin significantly increased tumor response rates in breast cancer patients when given before surgery.

At the annual meeting for the American Society of Clinical Oncology, the nation's premier association of clinical oncologists, Harry D. Bear, M.D., Ph.D., Chair, Division of Surgical Oncology at Virginia Commonwealth University Massey Cancer Center, presented the Avastin findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-40 clinical trial. Bear, who served as the trial's protocol chair, explained that Avastin, when added to preoperative chemotherapy regimens, increased toxicity but also increased pathologic complete response rates by more than 6 percent (34.5 percent versus 28.4 percent) and clinical complete response rates by approximately 8 percent (64.3 percent versus 55.8 percent). Pathologic complete response was defined in the study as no remaining invasive cancer left in the breast, and clinical complete response was defined as a complete disappearance of cancer with no evidence of disease progression. Patients with hormone receptor positive breast cancers appeared to benefit most from the treatment.

"While encouraging, the results of this study will probably not affect standard neoadjuvant or adjuvant chemotherapy practices in the near term," says Bear. "There are many different types of breast cancer, and we need more definitive biological predictors of response in order to more accurately identify the patients who will benefit most from Avastin."

Though hormone receptor positive patients benefited most from the addition of Avastin in the NSABP Protocol B-40 trial, a second study presented during the same session at the ASCO meeting seemed to contradict the findings. The second study, known as GeparQuinto, was conducted in Germany and found that Avastin benefitted patients with triple negative cancers, but not patients with hormone receptor positive cancers.

"The more we understand tumor biology, the more personalized cancer care becomes. By identifying the factors that made Avastin beneficial, we can hopefully test future breast cancer patients to determine whether or not it should be included in their treatment," says Bear.

The NSABP Protocol B-40 trial included 1,206 patients with operable HER2-negative breast cancer and tested different preoperative, or "neoadjuvant," chemotherapy regimens. The trial had two objectives. The first was to determine whether adding the chemotherapy agents capecitabine or gemcitabine to the standard neoadjuvant chemotherapy regimen of docetaxel followed by a combination of doxorubicin and cyclophosphamide increased the pathologic complete response rate. The second objective was to test whether adding Avastin to chemotherapy before surgery increased the pathologic complete response rate. While the addition of Avastin did improve the pathologic complete response rate, the addition of the chemotherapy agents capecitabine and gemcitabine did not.

"We need more research focusing on patient biology and tumor differences to understand why Avastin works for some but not others. We hope to gain insight by analyzing tumor biopsies and blood samples from patients in the B-40 trial and other recent Avastin studies," says Bear. "In addition, since the patients who received Avastin preoperatively also received it after surgery, it is possible the drug may improve long-term outcomes. We will follow these patients for many years to come to determine whether Avastin increased cure rates."


'/>"/>

Contact: Jenny Owen
Jrowen2@vcu.edu
804-628-2111
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. AMRI receives NIH contract award for development of pre-clinical drug candidates
2. University Hospitals Case Medical Center to begin clinical trial on experimental anti-TB drug
3. New clinical trial to examine medication to treat social withdrawal in Fragile X and autism
4. PACS improves radiologists use of clinical decision support systems
5. Wake Forest Baptist conducts clinical study for insomnia using new technology
6. Damon Runyon Cancer Research Foundation awards $3.45 million to 9 top young clinical investigators
7. Neuralstem updates clinical trial progress
8. Universal flu vaccine clinical trials show promise
9. Pioneering stem cell bandage receives approval for clinical trial
10. NIH grant for the move toward clinical trials targeting the lysosomal storage disease MPSIIIB
11. Clinical trials for new Alzheimers disease treatment to be awarded European Commission €6m funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... 2016 , ... PawPaws brand pet supplements owned by Whole Health ... the health of felines. The formula is all-natural and is made from Chinese herbs ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... -- Revolutionary technology includes multi-speaker listening to ... leaders in advanced audiology and hearing aid technology, has ... the world,s first internet connected hearing aid that opens ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... firsts,: , TwinLink™ - the first dual ...
Breaking Medicine Technology: